FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of November 2003
Commission File Number 0-16174
-------
Teva Pharmaceutical Industries Limited
--------------------------------------
(Translation of registrant's name into English)
5 Basel Street, P.O. Box 3190
Petach Tikva 49131 Israel
----------------------------------------
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
Form 20-F X Form 40-F
----- -----
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): _____
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): _____
Indicate by check mark whether by furnishing the information contained in
this Form, the registrant is also hereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
----- -----
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g(3)-2(b): 82-_____
1
As previously announced, on October 31, 2003, Teva Pharmaceutical
Industries Ltd., an Israeli corporation ("Teva"), SICOR Inc., a Delaware
corporation ("SICOR"), and Silicon Acquisition Sub, Inc., a Delaware corporation
and wholly owned subsidiary of Teva entered into an Agreement and Plan of Merger
(the "Merger Agreement"). The Merger Agreement is filed as Exhibit 10.1 and is
incorporated herein by reference. In connection with the Merger Agreement, Teva
and certain stockholders of SICOR entered into a Stockholders Agreement, dated
as of October 31, 2003 (the "Stockholders Agreement"). The Stockholders
Agreement is filed as Exhibit 10.2 and is incorporated herein by reference.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
(Registrant)
By: /s/ Dan Suesskind
------------------------------
Name: Dan Suesskind
Title: Chief Financial Officer
Date: November 5, 2003
3
EXHIBITS
Exhibit No. Description
10.1 Agreement and Plan of Merger, dated as of October 31, 2003, by
and among SICOR Inc., Teva Pharmaceutical Industries Ltd., and
Silicon Acquisition Sub, Inc.
10.2 Stockholders Agreement, dated as of October 31, 2003, between
Teva Pharmaceutical Industries Ltd. and certain SICOR
stockholders named therein
4